What is claimed is:

- 1. An isolated polypeptide selected from the group consisting of:
 - (i) an isolated polypeptide comprising an amino acid having at least 95% identity to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2;
 - (ii) an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2,
 - (iii) an isolated polypeptide that is the amino acid sequence of SEQ ID NO:2, and
 - (iv) a polypeptide that is encoded by a recombinant polynucleotide comprising the polyncleotide sequence of SEQ ID NO:1.
- 2. An isolated polynucleotide selected from the group consisting of:
- (i) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide that has at least 95% identity to the amino acid sequence of SEQ ID NO:2, over the entire length of SEQ ID NO:2;
- (ii) an isolated polynucleotide comprising a polynucleotide sequence that has at least 95% identity

over its entire length to a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2;

(iii) an isolated polynucleotide comprising a nucleotide sequence that has at least 95% identity

to that of SEQ ID NO:1 over the entire length of SEQ ID NO:1;

- (iv) an isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2;
- (v) an isolated polynucleotide that is the polynucleotide of SEQ ID NO: 1:
- (vi) an isolated polynucleotide of at least 30 nucleotides in length obtainable by screening an appropriate library under stringent hybridization conditions with a probe having the sequence of SEQ ID NO:1 or a fragment thereof of at least 30 nucleotides in length;
- (vii) an isolated polynucleotide encoding a mature polypeptide expressed by the tdk gene comprised in the *Streptococcus pneumoniae*; and
- (viii) a polynucleotide sequence complementary to said isolated polynucleotide of (i), (ii), (iii), (iv), (v), (vi) or (vii).

- 3. A method for the treatment of an individual:
- (i) in need of enhanced activity or expression of or immunological response to the polypeptide of claim 1 comprising the step of: administering to the individual a therapeutically effective amount of an antagonist to said polypeptide; or
 - (ii) having need to inhibit activity or expression of the polypeptide of claim 1 comprising:
 - (a) administering to the individual a therapeutically effective amount of an antagonist to said polypeptide; or
 - (b) administering to the individual a nucleic acid molecule that inhibits the expression of a polynucleotide sequence encoding said polypeptide;
 - (c) administering to the individual a therapeutically effective amount of a
 polypeptide that competes with said polypeptide for its ligand, substrate,
 or receptor; or
 - (d) administering to the individual an amount of a polypeptide that induces an immunological response to said polypeptide in said individual.
- 4. A process for diagnosing or prognosing a disease or a susceptibility to a disease in an individual related to expression or activity of the polypeptide of claim 1 in an individual comprising the step of:
- (a) determining the presence or absence of a mutation in the nucleotide sequence encoding said polypeptide in an organism in said individual; or
- (b) analyzing for the presence or amount of said polypeptide expression in a sample derived from said individual.
 - 5. A process for producing a polypeptide selected from the group consisting of:
- (i) an isolated polypeptide comprising an amino acid sequence selected from the group having at least 95% identity
 - to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2;
 - (ii) an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2;

- (iii) an isolated polypeptide that is the amino acid sequence of SEQ ID NO:2, and
- (iv) a polypeptide that is encoded by a recombinant polynucleotide comprising the polynucleotide sequence of SEQ ID NO:1,

comprising the step of culturing a host cell under conditions sufficient for the production of the polypeptide.

- 6. A process for producing a host cell comprising an expression system or a membrane thereof expressing a polypeptide selected from the group consisting of:
- (i) an isolated polypeptide comprising an amino acid sequence selected from the group having at least 95% identity

to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2;

- (ii) an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2;
- (iii) an isolated polypeptide that is the amino acid sequence of SEQ ID NO:2, and
- (iv) a polypeptide that is encoded by a recombinant polynucleotide comprising the polynucleotide sequence of SEQ ID NO:1,

said process comprising the step of transforming or transfecting a cell with an expression system comprising a polynucleotide capable of producing said polypeptide of (i), (ii), (iii) or (iv) when said expression system is present in a compatible host cell such the host cell, under appropriate culture conditions, produces said polypeptide of (i), (ii), (iii) or (iv).

- 7. A host cell or a membrane expressing a polypeptide selected from the group consisting of:
- (i) an isolated polypeptide comprising an amino acid sequence selected from the group having at least 95% identity to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2;
 - (ii) an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2;
 - (iii) an isolated polypeptide that is the amino acid sequence of SEO ID NO:2, and
- (iv) a polypeptide that is encoded by a recombinant polynucleotide comprising the polynucleotide sequence of SEQ ID NO:1.

- 8. An antibody immunospecific for the polypeptide of claim 1.
- 9. A method for screening to identify compounds that agonize or that inhibit the function of the polypeptide of claim 1 that comprises a method selected from the group consisting of:
- (a) measuring the binding of a candidate compound to the polypeptide (or to the cells or membranes bearing the polypeptide) or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound;
- (b) measuring the binding of a candidate compound to the polypeptide (or to the cells or membranes bearing the polypeptide) or a fusion protein thereof in the presence of a labeled competitor;
- (c) testing whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells or cell membranes bearing the polypeptide;
- (d) mixing a candidate compound with a solution comprising a polypeptide of claim 1, to form a mixture, measuring activity of the polypeptide in the mixture, and comparing the activity of the mixture to a standard; or
- (e) detecting the effect of a candidate compound on the production of mRNA encoding said polypeptide and said polypeptide in cells, using for instance, an ELISA assay.
 - 10. An agonist or antagonist to the polypeptide of claim 1.